Canada Markets closed

PreveCeutical Medical Inc. (PREV.CN)

Canadian Sec - Canadian Sec Real Time Price. Currency in CAD
Add to watchlist
0.0300+0.0025 (+9.09%)
At close: 2:07PM EST
Full screen
Previous Close0.0275
Open0.0300
Bid0.0200 x 0
Ask0.0300 x 0
Day's Range0.0250 - 0.0300
52 Week Range0.0200 - 0.0400
Volume93,000
Avg. Volume236,235
Market Cap15.351M
Beta (5Y Monthly)1.38
PE Ratio (TTM)N/A
EPS (TTM)-0.0080
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Newsfile

    PreveCeutical Files Provisional Patent Application for D-Amino Acid Peptides

    Vancouver, British Columbia--(Newsfile Corp. - November 24, 2021) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce it has filed a provisional application at the Australian Patent Office on November 18, 2021, entitled "Peptides and Uses Thereof", application number 2021903722, with the aim of seeking protection for certain peptides comprising D-amino acids and their use in methods of treating brain cancer.Compounds in th

  • Newsfile

    PreveCeutical Signs License Agreement for Exclusive Rights to Use UniQuest's Sol-Gel Technology for Delivery of Cannabinoids

    Vancouver, British Columbia--(Newsfile Corp. - November 18, 2021) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical" or the "Company"), is pleased to announce that it has signed a license agreement with UniQuest Pty Ltd. ("UniQuest") giving PreveCeutical exclusive rights to UniQuest's Sol-Gel ("Sol-Gel License") technology for the delivery of cannabinoids.The licence agreement provides PreveCeutical with the right to use the technology to deliver cannabinoids to

  • Newsfile

    PreveCeutical Receives AU$315,338 Research & Development Tax Incentive Cash Refund

    Vancouver, British Columbia--(Newsfile Corp. - August 31, 2021) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that it has received a AU$315,338 cash rebate from the Australian Federal Government's Research and Development ("R&D") Incentive Program. The cash refund is related to expenditure on eligible Australian R&D activities conducted during the financial year ended December 31, 2020. The R&D activities were across